CoChat
Sign Up
Cited by 2,609Dementia and Cognitive Impairment ResearchParkinson's Disease Mechanisms and TreatmentsNeurological disorders and treatments

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

Open access
Litvan, Irene, Goldman, Jennifer G., Tröster, Alexander I., Schmand, Ben A., Weintraub, Daniel, Petersen, Ronald C., Mollenhauer, Brit, Adler, Charles H. +8 more·2012·Movement Disorders
DOI 10.1002/mds.24893PMC PMC3641655
Open this paper in CoChat — free account

Abstract

Mild cognitive impairment is common in nondemented Parkinson's disease (PD) patients and may be a harbinger of dementia. In view of its importance, the Movement Disorder Society commissioned a task force to delineate diagnostic criteria for mild cognitive impairment in PD. The proposed diagnostic criteria are based on a literature review and expert consensus. This article provides guidelines to characterize the clinical syndrome and methods for its diagnosis. The criteria will require validation, and possibly refinement, as additional research improves our understanding of the epidemiology, presentation, neurobiology, assessment, and long‐term course of this clinical syndrome. These diagnostic criteria will support future research efforts to identify at the earliest stage those PD patients at increased risk of progressive cognitive decline and dementia who may benefit from clinical interventions at a predementia stage. © 2012 Movement Disorder Society

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mds.24893

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • To avoid arbitrary definitions of cognitive domains, the authors based their seven domains on the guidelines of the two most commonly used cognitive test batteries.

    “To avoid that the definition of cognitive domains would be arbitrary, we based our seven domains on the guidelines of the two most commonly used cognitive test batteries (Green et al., 2004; Litvan et al., 2012).”

    From Efficacy of non-invasive brain stimulation on cognitive functioning in brain disorders: a meta-analysis (2020) · cites this paper as Litvan et al., 2012

    The Neuropsychological Evaluation section says that assigning tests to domains is somewhat arbitrary and that the task force followed established conventions. The Level I and II criteria give guidelines for testing across five cognitive domains, so the paper is relevant to the citing authors’ domain definitions. It does not describe itself as one of the two most commonly used cognitive test batteries or prescribe seven domains. Page numbers were not supplied in our copy. (LLM, conf=0.84)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. [1]Litvan I Aarsland D Adler CH MDS task force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI Mov Disord 2011 26 1814 1824 21661055 PMC3181006
  2. [2]Hely MA Reid WG Adena MA Halliday GM Morris JG The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years Mov Disord 2008 23 837 844 18307261
  3. [3]Aarsland D Tandberg E Larsen JP Cummings JL Frequency of dementia in Parkinson disease Arch Neurol 1996 53 538 542 8660156
  4. [4]Aarsland D Andersen K Larsen JP Lolk A Kragh-Sorensen P Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study Arch Neurol 2003 60 387 392 12633150
  5. [5]Aarsland D Bronnick K Williams-Gray C Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis Neurology 2010 75 1062 1069 20855849 PMC2942065
  6. [7]Petersen RC Mild cognitive impairment as a diagnostic entity J Intern Med 2004 256 183 194 15324362
  7. [11]Janvin CC Larsen JP Aarsland D Hugdahl K Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia Mov Disord 2006 21 1343 1349 16721732
  8. [12]Janvin CC Aarsland D Larsen JP Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study J Geriatr Psychiatry Neurol 2005 18 149 154 16100104
  9. [13]Mahieux F Fenelon G Flahault A Manifacier MJ Michelet D Boller F Neuropsychological prediction of dementia in Parkinson’s disease J Neurol Neurosurg Psychiatry 1998 64 178 183 9489527 PMC2169963
  10. [14]Levy G Jacobs DM Tang MX Memory and executive function impairment predict dementia in Parkinson’s disease Mov Disord 2002 17 1221 1226 12465060
  11. [15]Jacobs DM Marder K Cote LJ Sano M Stern Y Mayeux R Neuropsychological characteristics of preclinical dementia in Parkinson’s disease Neurology 1995 45 1691 1696 7675228
  12. [16]Hobson P Meara J Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom Mov Disord 2004 19 1043 1049 15372593
  13. [17]Williams-Gray CH Evans JR Goris A The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort Brain 2009 132 2958 2969 19812213
  14. [19]Dubois B Burn D Goetz C Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force Mov Disord 2007 22 2314 2324 18098298
  15. [21]Hoops S Nazem S Siderowf AD Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease Neurology 2009 73 1738 1745 19933974 PMC2788810
  16. [22]Dalrymple-Alford JC MacAskill MR Nakas CT The MoCA: well-suited screen for cognitive impairment in Parkinson disease Neurology 2010 75 1717 1725 21060094
  17. [23]Villeneuve S Rodrigues-Brazete J Joncas S Postuma RB Latreille V Gagnon JF Validity of the Mattis Dementia Rating Scale to detect mild cognitive impairment in Parkinson’s disease and REM sleep behavior disorder Dement Geriatr Cogn Disord 2011 31 210 217 21474929
  18. [24]Pagonabarraga J Kulisevsky J Llebaria G Garcia-Sanchez C Pascual-Sedano B Gironell A Parkinson’s disease-cognitive rating scale: a new cognitive scale specific for Parkinson’s disease Mov Disord 2008 23 998 1005 18381647
  19. [25]Rossetti HC Lacritz LH Cullum CM Weiner MF Normative data for the Montreal Cognitive Assessment (MoCA) in a population-based sample Neurology 2011 77 1272 1275 21917776
  20. [27]Schinka JA Loewenstein DA Raj A Defining mild cognitive impairment: impact of varying decision criteria on neuropsychological diagnostic frequencies and correlates Am J Geriatr Psychiatry 2010 18 684 691 21399729 PMC3052876
  21. [28]Dalrymple-Alford JC Livingston L Macaskill MR Characterizing mild cognitive impairment in Parkinson’s disease Mov Disord 2011 26 629 636 21287603
  22. [29]Davis HS Rockwood K Conceptualization of mild cognitive impairment: a review Int J Geriatr Psychiatry 2004 19 313 319 15065223
  23. [30]Brown RG MacCarthy B Jahanshahi M Marsden CD Accuracy of self-reported disability in patients with parkinsonism Arch Neurol 1989 46 955 959 2528339
  24. [31]Naismith SL Pereira M Shine JM Lewis SJ How well do caregivers detect mild cognitive change in Parkinson’s disease? Mov Disord 2010 26 161 164 20818607
  25. [32]Caviness JN Driver-Dunckley E Connor DJ Defining mild cognitive impairment in Parkinson’s disease Mov Disord 2007 22 1272 1277 17415797
  26. [33]Dujardin K Dubois B Tison F Parkinson’s disease dementia can be easily detected in routine clinical practice Mov Disord 2010 25 2769 2776 20925065
  27. [34]Bangen KJ Jak AJ Schiehser DM Complex activities of daily living vary by mild cognitive impairment subtype J Int Neuropsychol Soc 2010 16 630 639 20374675 PMC2891154
  28. [35]Aarsland D Andersen K Larsen JP The rate of cognitive decline in Parkinson disease Arch Neurol 2004 61 1906 1911 15596611
  29. [36]Vendette M Gagnon JF Decary A REM sleep behavior disorder predicts cognitive impairment in Parkinson disease without dementia Neurology 2007 69 1843 1849 17984452
  30. [37]Mavandadi S Nazem S Ten Have TR Use of latent variable modeling to delineate psychiatric and cognitive profiles in Parkinson disease Am J Geriatr Psychiatry 2009 17 986 995 19855199 PMC2848973
  31. [38]Peralta C Stampfer-Kountchev M Karner E Orthostatic hypotension and attention in Parkinson’s disease with and without dementia J Neural Transm 2007 114 585 588 17195917
  32. [39]Witjas T Kaphan E Azulay JP Nonmotor fluctuations in Parkinson’s disease: frequent and disabling Neurology 2002 59 408 413 12177375
  33. [40]Lezak MD Howieson DB Loring DW Neuropsychological Assessment 4 New York Oxford University Press: Oxford University Press 2004
  34. [42]Caballol N Marti MJ Tolosa E Cognitive dysfunction and dementia in Parkinson disease Mov Disord 2007 22 Suppl 17 S358 S366 18175397
  35. [43]Muslimovic D Schmand B Speelman JD de Haan RJ Course of cognitive decline in Parkinson’s disease: a meta-analysis J Int Neuropsychol Soc 2007 13 920 932 17942010
  36. [44]Tröster AI Neuropsychological characteristics of dementia with Lewy bodies and Parkinson’s disease with dementia: differentiation, early detection, and implications for “mild cognitive impairment” and biomarkers Neuropsychol Rev 2008 18 103 119 18322801
  37. [45]Bothe MR Uttner I Otto M Sharpening the boundaries of Parkinson-associated dementia: recommendation for a neuropsychological diagnostic procedure J Neural Transm 2010 117 353 367 20119649
  38. [46]Foltynie T Brayne CE Robbins TW Barker RA The cognitive ability of an incident cohort of Parkinson’s patients in the UK The CamPaIGN study Brain 2004 127 550 560 14691062
  39. [47]Tröster AI Woods SP Morgan EE Assessing cognitive change in Parkinson’s disease: development of practice effect-corrected reliable change indices Arch Clin Neuropsychol 2007 22 711 718 17644304
  40. [49]Mollenhauer B Trenkwalder C Neurochemical biomarkers in the differential diagnosis of movement disorders Mov Disord 2009 24 1411 1426 19412961
  41. [50]Mollenhauer B Trenkwalder C von Ahsen N Beta-amlyoid 1–42 and tau-protein in cerebrospinal fluid of patients with Parkinson’s disease dementia Dement Geriatr Cogn Disord 2006 22 200 208 16899997
  42. [51]Siderowf A Xie SX Hurtig H CSF amyloid {beta> 1–42 predicts cognitive decline in Parkinson disease Neurology 2010 75 1055 1061 20720189 PMC2942062
  43. [52]Foltynie T Lewis SG Goldberg TE The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson’s disease J Neurol 2005 252 833 838 15772739
  44. [53]Guerini FR Beghi E Riboldazzi G BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson’s disease Eur J Neurol 2009 16 1240 1245 19538209
  45. [54]Gattellaro G Minati L Grisoli M White matter involvement in idiopathic Parkinson disease: a diffusion tensor imaging study Am J Neuroradiol 2009 30 1222 1226 19342541 PMC7051338
  46. [55]Alves G Bronnick K Aarsland D CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s disease: the Norwegian ParkWest study J Neurol Neurosurg Psychiatry 2010 81 1080 1086 20547614
  47. [56]Setó-Salvia N Clarimon J Pagonabarraga J Dementia risk in Parkinson disease: disentangling the role of MAPT haplotypes Arch Neurol 2011 68 359 364 21403021
  48. [58]Gill DJ Freshman A Blender JA Ravina B The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson’s disease Mov Disord 2008 23 1043 1046 18381646
  49. [59]Kulisevsky J Pagonabarraga J Cognitive impairment in Parkinson’s disease: tools for diagnosis and assessment Mov Disord 2009 24 1103 1110 19353727
  50. [60]Verbaan D Marinus J Visser M Cognitive impairment in Parkinson’s disease J Neurol Neurosurg Psychiatry 2007 78 1182 1187 17442759 PMC2117586
  51. [61]Llebaria G Pagonabarraga J Kulisevsky J Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson’s disease Mov Disord 2008 23 1546 1550 18546326

Cited by

Sorted by citations

Authors
Litvan, I., Goldman, J. G., Tröster, A. I., Schmand, B. A., Weintraub, D., Petersen, R. C., Mollenhauer, B., Adler, C. H., Marder, K., Williams‐Gray, C. H., Aarsland, D., Kulisevsky, J., Rodriguez‐Oroz, M. C., Burn, D. J., Barker, R. A., & Emre, M.
Affiliations
  • University of Louisville (US)
  • Rush University Medical Center (US)
  • University of North Carolina at Chapel Hill (US)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Mental Illness Research, Education and Clinical Centers (US)
  • Mayo Clinic (US)
  • Paracelsus Elena Klinik Kassel (DE)
  • Mayo Clinic in Arizona (US)
  • NewYork–Presbyterian Hospital (US)
  • University of Cambridge (GB)
  • University of Oslo (NO)
  • Universitat Autònoma de Barcelona (ES)
  • Newcastle University (GB)
  • Istanbul University (TR)
Corresponding author
Litvan, Irene
ORCID
Venue
Movement Disorders
Publisher
Wiley
Published
2012-01-24
Volume
27
Issue
3
Pages
349-356
ISSN
  • 0885-3185 (ISSN-L)
  • 1531-8257
DOI
10.1002/mds.24893
PMC
PMC3641655
OpenAlex
W2156013560
Cited by
2,609
References
8
Citations by year
2026: 195 · 2025: 254 · 2024: 241 · 2023: 186 · 2022: 232 · 2021: 234 · 2020: 211 · 2019: 188 · 2018: 180 · 2017: 165 · 2016: 144 · 2015: 133 · 2014: 111 · 2013: 97 · 2012: 33
FWCI
16.15
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Movement Disorders (publishedVersion)
  • PubMed (publishedVersion)
  • UvA-DARE (University of Amsterdam) (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • GRO (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • UNC Libraries
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • Michael J. Fox Foundation for Parkinson's Research
  • National Parkinson Foundation
  • Parkinson's Disease Foundation
  • Pfizer
  • GlaxoSmithKline
  • Teva Pharmaceutical Industries
  • Boston Scientific Corporation
  • Parkinson's UK
  • University of Cambridge
  • University of Oxford
  • European Commission
  • H. Lundbeck A/S
  • National Institutes of Health (AG016574, NS36630, RR024156, AG006786)
  • St. Jude Medical
  • Parkinsonfonden
  • National Institute on Aging (U01AG006786, R01AG024040, P50AG016574)
  • National Institute of Mental Health (K23MH067894)
  • National Institute of Neurological Disorders and Stroke (R56NS036630, R01NS036630)
  • National Center for Research Resources (UL1RR024156)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Health Sciences › Medicine › Neurology › Neurological disorders and treatments
Keywords
mild cognitive impairment, Parkinson's disease, diagnostic criteria, dementia risk, cognitive decline, pre-dementia, expert consensus
MeSH terms
Humans, Neuropsychological Tests, Parkinson Disease, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review